[CAS NO. 1054312-81-0] FK-3000
PRODUCTS SPECIFICATIONS [1054312-81-0]
DESCRIPTION [1054312-81-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 417.45 |
| Molecular Formula | C22H27NO7 |
| SMILES | COC1=C([C@]([H])(C2)NCC3)[C@]3(C4=C2C=CC(OC)=C4OC(C)=O)C[C@H](OC(C)=O)[C@@H]1O |
Summary
In Vitro
FK-3000 (0-5 μg/mL; 48 h) inhibits cell proliferation, with IC
50
s of 0.52, 0.77, 0.22, 2.70, 0.40, and 1.90 μg/mL for MDA-MB-231, MCF-7, PC-3, A-431, HT-29, and CT-26 cells, respectively
[1]
.
FK-3000 (0.5-5.0 μg/mL; 24-48 h) induces MDA-MB-231 cell apoptosis in a dose- and time-dependent manner
[1]
.
FK-3000 (0.5-5.0 μg/mL; 24-48 h) induces G
2
/M phase arrest in MDA-MB-231 and MCF-7 cells in a dose- and time-dependent manner
[2]
.
FK-3000 (0.5-5.0 μg/mL; 60-120 min or 24-48 h) reduces NF-κB phosphorylation levels and COX-2 expression in MDA-MB-231 cells
[1]
.
FK-3000 (5.0 μg/mL; 120 min) effectively blocks NF-κB translocation from cytoplasm to nucleus in MDA-MB-231 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
FK-3000 (1 mg/kg/day; i.p. daily for 24 d) inhibits tumor growth and shows no signs of toxicity in an MDA-MB-231 xenografted mouse model
[1]
.
FK-3000 (10-25 mg/kg; p.o. for 10 d) significantly delays skin lesion, limits the development of further lesions and prolongs the mean survival time of HSV-1 infected mice
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Xu HD, et, al. FK-3000 isolated from Stephania delavayi Diels. inhibits MDA-MB-231 cell proliferation by decreasing NF-κB phosphorylation and COX-2 expression. Int J Oncol. 2015;46(6):2309-16.
- [2] Li YC, et, al. 6,7-di-O-acetylsinococuline (FK-3000) induces G2/M phase arrest in breast carcinomas through p38 MAPK phosphorylation and CDC25B dephosphorylation. Int J Oncol. 2015 Feb;46(2):578-86.
- [3] Nawawi A, et, al. In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1. Phytother Res. 2001 Sep;15(6):497-500.
- [4] Lee JH, et, al. Development of a LC-MS method for quantification of FK-3000 and its application to in vivo pharmacokinetic study in drug development. J Pharm Biomed Anal. 2012 Nov;70:587-91.